Cardiac strain in patients on Janus Kinase inhibitors for rheumatic diseases: a 1-year echocardiographic study
Authors' conclusion
In this cohort, JAKi did not result in significant changes in cardiac strain or function over one year in patients with ARDs, suggesting that JAKi may not have a detrimental impact on cardiac function in the short term.
Study context
- Population
- Patients with RA, PsA or axSpA initiating a janus kinase inhibitors (JAKi) in routine clinical practice, Greececompleted the study
- Participants
- 30 patients
- Exposure
- JAKi: 12 months vs baseline
- axSpAn = 12
- RAn = 10
- PsAn = 8
- Outcome
- Cardiac strain and function: GLS, EF, RV function (RV GLS, TAPSE, S'RV), diastolic function (E/A, E/E')
- Follow-up
- 12 months
Methodological detailssingle-group, before–after (baseline, 6 and 12 months), speckle-tracking echocardiography
- Single-group
- Before–after (baseline, 6 and 12 months)
- Speckle-tracking echocardiography
Main finding
As reported in the abstract
Cardiac strain and function · baseline to 12 months
- No significant changes in global longitudinal strain (GLS), ejection fraction (EF), E/A, E/E', TAPSE, S'RV or heart rate
- GLS of the left ventricle did not decline
Observational data: associations, not effects.
Further findings
Disease activity
- Significantly improved across all cohorts
Original publication
Cardiac strain in patients on Janus Kinase inhibitors for rheumatic diseases: a 1-year echocardiographic study. Clin Exp Rheumatol. Published 27 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →